2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Saturday, May 2, 2020

11:00AM-12:00PM: Abstract Number: 007

Dense Genotyping of Immunologic Loci Identifies CXCR4 as a Novel Susceptibility Locus for Systemic Juvenile Idiopathic Arthritis

Plenary Abstracts Session 3

11:00AM-12:00PM: Abstract Number: 009

Emapalumab (Anti-Interferon-Gamma Monoclonal Antibody) in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA)

Plenary Abstracts Session 3

11:00AM-12:00PM: Abstract Number: 010

Experience with and Management of HLH-like Toxicities Following Chimeric Antigen Receptor T-Cell Therapy for Treatment of Relapsed/Refractory Pre-B ALL

Plenary Abstracts Session 3

11:00AM-12:00PM: Abstract Number: 008

Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases

Plenary Abstracts Session 3

4:15PM-5:15PM: Abstract Number: 165

A Massively Parallel Reporter Assay Screen of Genetic Variants on JIA Haplotypes Reveals Variants Associated with Altered Function of an Intergenic Enhancer in the HLA Class II Locus

Poster Session 3

4:15PM-5:15PM: Abstract Number: 188

A New Multidisciplinary Pediatric SLE Clinic in a Large Urban Care Center: Feasibility, Patient Satisfaction, and Quality After One Year

Poster Session 3

4:15PM-5:15PM: Abstract Number: 184

A Survey of Uveitis Knowledge Among Juvenile Arthritis Patients and Parents

Poster Session 3

4:15PM-5:15PM: Abstract Number: 119

Actual Medication Usage of Patients with Juvenile Onset Systemic Lupus Erythematosus Using Japanese Health Insurance Database

Poster Session 3

4:15PM-5:15PM: Abstract Number: 186

Anthropometric Assessment and Food Intake of Parents of Pediatric Patients with Chronic Rheumatic Diseases

Poster Session 3

4:15PM-5:15PM: Abstract Number: 145

Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA

Poster Session 3

4:15PM-5:15PM: Abstract Number: 163

Anti-Dense Fine Speckled (DFS) Autoantibodies in Autoinflammatory Vasculopathies

Poster Session 3

4:15PM-5:15PM: Abstract Number: 130

Anti-Ro/SSA Is Associated with Progression to End-Stage Renal Disease in Anti-dsDNA Positive Lupus Nephritis

Poster Session 3

4:15PM-5:15PM: Abstract Number: 115

Carbohydrate and Sugar Intake Predict Pain in Teens with Active JIA Disease but Not in Teens in Remission or Controls: A Cross-Sectional, Case-Control Metabolomics Pilot Study

Poster Session 3

4:15PM-5:15PM: Abstract Number: 160

CD3 Downregulation on T-cells Is Concomitant with Arginase Upregulation on Myeloid Cells in Synovial Fluid of Patients with Juvenile Idiopathic Arthritis

Poster Session 3

4:15PM-5:15PM: Abstract Number: 120

Characteristics of the New Childhood Arthritis and Rheumatology Research Alliance Registry of Juvenile Myositis Patients Enrolled in the First Two Years

Poster Session 3

1
2
3
…
5
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].